Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507018 | 0.89 | MRGPRX4 (0.47) | MRGPRX4SMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL6499919 | 0.79 | KMT2A (0.38) | RARGRORCSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8305282 | 0.74 | NR1H2 (0.35) | GABRA1GABRA2SCN9ASMN1; SMN2PPARG | |
| SCHEMBL6505997 | 0.73 | MRGPRX4 (0.48) | MRGPRX4SMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL8942727 | 0.73 | MRGPRX4 (0.47) | MRGPRX4SCN9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6501925 | 0.72 | MAPT (0.53) | SMN1; SMN2ALDH1A1KMT2ALMNAHPGD | |
| SCHEMBL6497856 | 0.71 | MRGPRX4 (0.47) | MRGPRX4SCN9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8301628 | 0.70 | MRGPRX4 (0.48) | MRGPRX4SMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL8942950 | 0.69 | MRGPRX4 (0.48) | MRGPRX4SCN9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL26766260 | 0.66 | PDE2A (0.41) | SMN1; SMN2ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009834-A1 | Azole compounds, process for preparation of the same and use thereof | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1386915-A1 | AZOLE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-02-04 | — | — | EP | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-20050009834-A1 | Azole compounds, process for preparation of the same and use thereof | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1386915-A1 | AZOLE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009834-A1 | Azole compounds, process for preparation of the same and use thereof | C1S, CYP4B1, CYP4X1 | MAPK14 3693/4885MRGPRX4 440/4885GABRA1 958/4885 |
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MAPK14 4087/4885MRGPRX4 833/4885GABRA1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.